Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's19 enrolled

Overview

Patients with hypertrophic cardiomyopathy are being compared to a control group. IMR will be assessed with a pressure wire. Clinical f/u at 3 months and 6 months and a 48 hour holter monitor.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hypertrophic Cardiomyopathy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-80 * Already have an indication for coronary angiography * Previous diagnosis of hypertrophic cardiomyopathy (unless control) Exclusion Criteria: * Fractional flow reserve found to be significant (FFR \< 0.8) * Already have a condition associated with or likely to be associated with an elevated IMR (diabetes, cardiac syndrome X, takotsubo cardiomyopathy, hypertensive cardiomyopathy, severe aortic stenosis, STEMI)

Locations (1)

London Health Sciences Centre

London, Canada

Outcomes

Primary Outcomes

IMR in patients with hypertrophic cardiomyopathy (HCM) versus controls

Time frame: 1 day

Secondary Outcomes

Number of ventricular tachycardia

Measured during 48 h recording after 6 months

Time frame: 6 months

Chest pain - Canadian Cardiovascular Society (CCS) class

Time frame: Up to 6 months

Shortness of breath - NYHA class

Time frame: Up to 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.